Imaoka, Takeshi
Eli Lilly (Japan)
3 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 226
- Verified
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 131
- Verified
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme)
Kiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 30
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free